Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOP: JAK Inhibitor Discontinuation in Ulcerative Colitis
NCT07718529Phase 4Not yet recruiting
- Sponsor
- Assistance Publique-Hôpitaux de Marseille
- Start
- Jan 2027
- Primary completion
- Jan 2030
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in ulcerative colitis (UC) (2 arms), sponsored by Assistance Publique-Hôpitaux de Marseille. Primary endpoint: Composite criterion of treatment safety, efficacy, and patient satisfaction at 52 weeks. Planned start Jan 2027; status: not yet recruiting.
02
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT07718529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07718529.